Associated tags: EHR, Map, Patient, Cancer, Genetic testing, Risk assessment, Breast cancer, Pharmaceutical industry, Nursing, Genetics, NCCN
Locations: UNITED STATES, NORTH AMERICA, NASHUA, NH, US, CHICAGO, ILLINOIS, LATIN AMERICA, NEW YORK, MASSACHUSETTS
CHICAGO, April 19, 2024 /PRNewswire-PRWeb/ -- CancerIQ, a best-in-class cancer-focused precision health platform, today announced it is seeking health systems to participate in the newly launched, large-scale research effort that will document the downstream revenue of digital interventions for genetically informed cancer prevention, early detection and treatment. The "Validating Applications for Long-term Utility and Enhanced ROI" (VALUE) in Cancer Risk Programs Study aims to bring together health systems from across the country to advance understanding of the system-level financial value of genetics and genomics.
Key Points:
- "For maximum benefit, health scientists recommend integrating cancer genetics and genomics into everyday patient care," said Jeffrey Weitzel, MD, principal investigator of the VALUE in Cancer Risk Programs Study and strategic advisor to CancerIQ.
- The VALUE in Cancer Risk Programs Study is led and organized by CancerIQ.
- "We anticipate the VALUE in Cancer Risk Programs Study will provide important insights to support the expansion of lifesaving precision health resources."
- The VALUE in Cancer Risk Programs Study invites health system partners to contribute to this important research effort.
Oncology,
Health,
Technology,
Hospitals,
Genetics,
Software,
Genomics,
Organization,
Genetic testing,
Risk,
Patient,
Mortality,
AI,
Risk assessment,
Moonshot,
Breast cancer,
Multimedia,
Pharmaceutical industry CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment.
Key Points:
- CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment.
- The profiles of the honorees are featured in the April 8, 2024 issue of MH magazine and online at ModernHealthcare.com/Innovator-Awards .
- “The role of innovation has always been paramount in healthcare, and our 2024 honorees as top Innovators are driving real change in the industry,” said Mary Ellen Podmolik, editor in chief of Modern Healthcare.
- She has driven adoption of the platform across 225 diverse clinical locations and specialties to make a direct patient impact.
Retrieved on:
Thursday, February 1, 2024
CHICAGO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- CancerIQ, the platform enabling health systems to use genetic information to prevent, detect, and treat cancer at scale, announced today that industry leader Diedre Mavin Senatra has joined the team as Senior Vice President of Commercial Strategy.
Key Points:
- Senatra joins CancerIQ at a critical time, as providers must update protocols to meet expanded industry guidelines for cancer risk assessment and genetic testing — and are increasingly seeking out CancerIQ as a solution.
- CHICAGO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- CancerIQ , the platform enabling health systems to use genetic information to prevent, detect, and treat cancer at scale, announced today that industry leader Diedre Mavin Senatra has joined the team as Senior Vice President of Commercial Strategy.
- Senatra joins CancerIQ at a critical time, as providers must update protocols to meet expanded industry guidelines for cancer risk assessment and genetic testing — and are increasingly seeking out CancerIQ as a solution.
- Senatra is well-respected in the hereditary cancer genetics and genomics industry.
Retrieved on:
Thursday, December 21, 2023
Natera,
Partnership,
Risk,
Division,
Research,
Breast Cancer Research Foundation,
Cancer Moonshot,
City,
NCCN,
MD,
Society,
Panel,
Education,
Cancer,
Genetics,
Genomics,
University,
Breast cancer,
Genetic testing,
Patient,
Diagnosis,
American School,
FACP,
Pharmaceutical industry CHICAGO, Dec. 21, 2023 /PRNewswire-PRWeb/ -- CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, announced today that Jeffrey Weitzel, MD, cofounder of the City of Hope Clinical Cancer Genomics Community of Practice, was named an official strategic advisor to the company. In this role, Dr. Weitzel's deep, cross-sector expertise will help inform research and product development and enrich CancerIQ's longstanding commitment to mainstreaming cancer genetics as part of routine care.
Key Points:
- CHICAGO, Dec. 21, 2023 /PRNewswire-PRWeb/ -- CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, announced today that Jeffrey Weitzel, MD, cofounder of the City of Hope Clinical Cancer Genomics Community of Practice, was named an official strategic advisor to the company.
- "As a strategic advisor to CancerIQ, I look forward to driving continued innovation in this space."
- As a strategic advisor, Dr. Weitzel will work with CancerIQ to advance translational research in the delivery of cancer genetics and genomics.
- "As a strategic advisor to CancerIQ, I look forward to driving continued innovation in this space."
Retrieved on:
Monday, November 20, 2023
Breast,
RSNA,
Suite,
EHR,
Research,
NCCN,
Inc.,
AUC,
Risk,
ICAD,
Breast cancer,
Patient,
Mammography,
Risk assessment,
2D,
Radiology,
Cancer,
Partnership,
3D,
Density,
Physician,
Medical imaging Offering radiology the most complete breast health solution, including breast density assessment, breast cancer detection, and thorough risk evaluation, including lifetime, genetic, and short-term 1- or 2-year AI-risk
Key Points:
- Offering radiology the most complete breast health solution, including breast density assessment, breast cancer detection, and thorough risk evaluation, including lifetime, genetic, and short-term 1- or 2-year AI-risk
NASHUA, N.H. and CHICAGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc .
- (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, and CancerIQ , the precision cancer prevention platform streamlining provider workflows and activating high-risk patients, today announced a new partnership to create a best-in-class breast health care solution.
- Integrated with leading EHR workflows, CancerIQ’s lifetime risk calculator offers Tyrer-Cuzick scores (7 and 8), Gail, and NCCN guidelines.
- The ProFound Risk platform has a proven track record of predicting risk of breast cancer 2.4x more accurately in the next year than traditional lifetime risk models1.
Retrieved on:
Thursday, December 7, 2023
POC,
Associate professor,
Entrepreneurship,
Cancer,
Genetic counseling,
Risk,
Patient,
Trust,
Genetic testing,
Biomarker,
Risk assessment,
Public health,
Doctor of Philosophy,
Pharmaceutical industry,
MD,
Epidemiology CHICAGO, Dec. 7, 2023 /PRNewswire-PRWeb/ -- To identify more equitable models for cancer genetic testing, a team of researchers from Boston University School of Public Health and CancerIQ examined racial/ethnic disparities along the continuum of cancer genetic service delivery. The goal of the study was to identify specific areas of patient attrition along clinical workflows to improve genetic testing processes and reduce racial disparities in cancer genetic testing. Results were published in the peer-reviewed Cancer, Epidemiology, Biomarkers and Prevention.
Key Points:
- The goal of the study was to identify specific areas of patient attrition along clinical workflows to improve genetic testing processes and reduce racial disparities in cancer genetic testing.
- "Now that we have more information about what is driving disparities in genomic testing and how to solve for it, we need to put it into clinical practice."
- Fewer than 1 in 5 high-risk individuals receive genetic testing, and most of those patients have not discussed testing with a healthcare provider.
- This study demonstrates providers equipped to discuss and act on the results of cancer risk assessment with patients at the point-of-care may improve genetic counseling rates and eliminate disparities in testing uptake among racial/ethnic minority groups.
Retrieved on:
Sunday, November 26, 2023
Radiology,
Navigation,
Breast,
RSNA,
NCCN,
Accreditation,
Mammography Quality Standards Act,
Breast cancer,
Patient,
Electronic health record,
Algorithm,
FDA,
Intelligence,
American College,
EQUIP,
Machine learning,
First Ever,
American College of Radiology,
Deep learning,
Buffer,
Partnership,
ACR,
Education,
Medical device,
Nursing "Our collaboration with CancerIQ reflects our commitment to furnishing care providers with best-in-class solutions for breast health," said Mo Abdolell, founder and CEO, Densitas.
Key Points:
- "Our collaboration with CancerIQ reflects our commitment to furnishing care providers with best-in-class solutions for breast health," said Mo Abdolell, founder and CEO, Densitas.
- Densitas offers a robust AI-driven mammography quality assurance platform that comprises intelliMammo® and intelliMaven™.
- This integrated platform provides mammography facilities and clinical care teams with a comprehensive and scalable solution that boosts operational efficiency, improves mammography quality, and increases clinical confidence.
- Importantly, it ensures compliance with the FDA's Mammography Quality Standards Act (MQSA) EQUIP and the American College of Radiology's standards.
Retrieved on:
Friday, November 17, 2023
CHICAGO, Nov. 17, 2023 /PRNewswire-PRWeb/ -- CancerIQ, the platform powering early cancer detection and prevention across patient populations, today announced it has successfully completed a rigorous risk assessment and security audit of its platform and achieved SOC 2 Type 2 Compliance from AssuranceLab, a compliance auditing company focused on cloud-native platforms.
Key Points:
- "SOC 2 Type 2 Compliance demonstrates that CancerIQ has gone through rigorous testing and is a trusted platform for empowering health systems to scale genetically informed cancer care."
- Receiving SOC 2 Type 2 Compliance attests that a software product and its related services and processes meet industry-standard security and privacy protocols.
- SOC 2 Type 2 Compliance indicates that CancerIQ has the governance, infrastructure, and systems in place to protect patient information from unauthorized access both from within and outside a health system.
- CancerIQ selected AssuranceLab, which specializes in audits of cloud-native solutions in healthcare and other industries.
Oncology,
Health,
Technology,
Hospitals,
Genetics,
Managed Care,
Software,
University,
Associate professor,
Genetics in Medicine,
Risk assessment,
University of Washington School of Public Health,
Cancer,
Doctor of Philosophy,
Boston University School of Public Health,
Genetic counseling,
Public health,
Patient,
Genetic testing,
Research,
Conference,
Vaccine,
Nursing,
Pharmaceutical industry,
Medicine National efforts have called for increased access to genetic counseling and testing for hereditary cancers among at-risk individuals.
Key Points:
- National efforts have called for increased access to genetic counseling and testing for hereditary cancers among at-risk individuals.
- Research shows the average uptake of genetic counseling after referral is often 16% or lower, reflecting complex barriers to access and clinical workflow challenges.
- At-risk patients in the study then received follow-up genetic testing through one of four workflows: a traditional referral model, point-of-care scheduling, point-of-care counseling/telegenetics, and point-of-care genetic testing.
- “Together these strategies can expand access to genetic testing that is essential to improve cancer outcomes at the population level.”
To meet the growing need for point-of-care genetic resources, CancerIQ recently launched full-service virtual navigation and genetic counseling services: CancerIQ Complete .
Sociology,
University,
Providence St. Joseph Health,
Education,
Woman,
Henry Ford Health,
Pharmacy,
Falls,
Doctor of Philosophy,
Government,
Clover Health,
Alameda Health System,
Series,
Management,
Pharmaceutical industry,
Nursing CHICAGO, April 18, 2023 /PRNewswire-PRWeb/ -- CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, today announced Carladenise Edwards, PhD, a dedicated leader with more than three decades of experience in healthcare, government and technology, as the newest member of its board of directors.
Key Points:
- CHICAGO, April 18, 2023 /PRNewswire-PRWeb/ -- CancerIQ , the platform powering early cancer detection and prevention across broad patient populations, today announced Carladenise Edwards, PhD, a dedicated leader with more than three decades of experience in healthcare, government and technology, as the newest member of its board of directors.
- "Carladenise's firsthand experience delivering results and exceeding growth targets for large health systems makes her an invaluable addition to CancerIQ's board," said Feyi Ayodele, CEO and co-founder of CancerIQ.
- Transitioning away from the health system C-suite, Dr. Edwards now serves as strategic advisor and board member for well-established healthcare companies such as Clover Health and Heluna Health.
- Dr. Edwards adds health system experience to a board already made up of members with diverse professional backgrounds, including experts in pharmacy, IT, investing, and life sciences.
